lasn01
mAbexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jun 6, 2022 (NCT05331300)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Interleukin 11 receptor alphaINHIBITOR
IL11RA inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06226545 | Phase 2 | Mar 5, 2024 | Lassen Therapeutics Inc. |
| NCT05331300 | Phase 1 | Jun 6, 2022 | — |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Lassen Therapeutics Inc. | For profit | 1 | 1 | 1 | 2024 |
1 organizations
Page 1 / 1